These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 30382902

  • 1. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study.
    Tien YC, Yen HH, Li CF, Liu MP, Hsue YT, Hung MH, Chiu YM.
    Arthritis Res Ther; 2018 Nov 01; 20(1):246. PubMed ID: 30382902
    [Abstract] [Full Text] [Related]

  • 2. Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs: a nested case-control study.
    Hung MH, Tien YC, Chiu YM.
    Adv Rheumatol; 2021 Apr 08; 61(1):22. PubMed ID: 33832541
    [Abstract] [Full Text] [Related]

  • 3. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
    Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, Lan JL, Chen DY.
    Int J Rheum Dis; 2019 Jun 08; 22(6):1145-1151. PubMed ID: 31117160
    [Abstract] [Full Text] [Related]

  • 4. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct 08; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 5. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.
    Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S.
    Ann Rheum Dis; 2017 Jun 08; 76(6):1051-1056. PubMed ID: 27934678
    [Abstract] [Full Text] [Related]

  • 6. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J, Li W, Peng X, Tan Z, Tan M, Zhang C, Wang W, Xu Z, Zhou G.
    Int Urol Nephrol; 2017 Mar 08; 49(3):475-482. PubMed ID: 28032257
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, Burmester G, Walls C, Wu WS, Dickson C, Liao R, Genovese MC.
    RMD Open; 2020 Feb 08; 6(1):. PubMed ID: 32098857
    [Abstract] [Full Text] [Related]

  • 8. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH, Bae SC, Song GG.
    Int J Rheum Dis; 2013 Oct 08; 16(5):527-31. PubMed ID: 24164839
    [Abstract] [Full Text] [Related]

  • 9. Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhang A, Wu Y, Tan Y, Shi J, Zhao Y, Hu Y, Yu J, Zheng W, Lai X, Zhang M, Zhu Y, Ye Y, Huang Y, Fu S, Huang H, Luo Y.
    Biol Blood Marrow Transplant; 2020 May 08; 26(5):956-964. PubMed ID: 31962163
    [Abstract] [Full Text] [Related]

  • 10. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
    Kuo MH, Tseng CW, Ko PH, Wang ST, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS.
    Liver Int; 2024 Feb 08; 44(2):497-507. PubMed ID: 38010984
    [Abstract] [Full Text] [Related]

  • 11. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, Auran T, Loundou A, Motte A, Ressiot E, Norguet E, Chabannon C, Bouabdallah R, Tamalet C, Gérolami R.
    J Viral Hepat; 2010 Nov 08; 17(11):807-15. PubMed ID: 20002298
    [Abstract] [Full Text] [Related]

  • 12. Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (booster effect).
    Azarkeivan A, Karimi G, Shaiegan M, Maghsudlu M, Tabbaroki A.
    Pediatr Hematol Oncol; 2009 Jun 08; 26(4):195-201. PubMed ID: 19437322
    [Abstract] [Full Text] [Related]

  • 13. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.
    Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gérolami R.
    Arthritis Res Ther; 2009 Jun 08; 11(6):R179. PubMed ID: 19941642
    [Abstract] [Full Text] [Related]

  • 14. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.
    Hong X, Xiao Y, Xu L, Liu L, Mo H, Mo H.
    Immun Inflamm Dis; 2023 Feb 08; 11(2):e780. PubMed ID: 36840482
    [Abstract] [Full Text] [Related]

  • 15. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S.
    Eur J Haematol; 2010 Sep 08; 85(3):243-50. PubMed ID: 20491883
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
    Loggi E, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, Scuteri A, Vitale G, Di Donato R, Cursaro C, Furlini G, Andreone P.
    J Clin Virol; 2017 Aug 08; 93():66-70. PubMed ID: 28654775
    [Abstract] [Full Text] [Related]

  • 17. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
    Chiu YM, Lai MS, Chan KA.
    PLoS One; 2018 Aug 08; 13(4):e0196210. PubMed ID: 29694398
    [Abstract] [Full Text] [Related]

  • 18. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.
    Mücke VT, Mücke MM, Peiffer KH, Weiler N, Welzel TM, Sarrazin C, Zeuzem S, Berger A, Vermehren J.
    Aliment Pharmacol Ther; 2017 Aug 08; 46(4):432-439. PubMed ID: 28627791
    [Abstract] [Full Text] [Related]

  • 19. Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation.
    Ohkubo M, Seo E, Doki K, Suzuki Y, Sekine I, Homma M.
    Biol Pharm Bull; 2024 Aug 08; 47(5):941-945. PubMed ID: 38735754
    [Abstract] [Full Text] [Related]

  • 20. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients.
    Schwaneck EC, Krone M, Kreissl-Kemmer S, Weißbrich B, Weiss J, Tony HP, Gadeholt O, Schmalzing M, Geier A.
    Clin Rheumatol; 2018 Nov 08; 37(11):2963-2970. PubMed ID: 30238380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.